NCT00589823View on ClinicalTrials.gov

Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

PHASE3CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Cancers, Pain
Interventions
DRUG

Fentanyl citrate

nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day

DRUG

Immediate release morphine sulphate

drug dose as required by patient taken to treat up to four epsiodes of BTCP per day

Trial Locations (1)

Unknown

Prof Fallon, Edinburgh

All Listed Sponsors
lead

Archimedes Development Ltd

INDUSTRY

NCT00589823 - Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids | Biotech Hunter | Biotech Hunter